Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal

Gilead Sciences and Arcellx have been collaborating on the multiple myeloma cell therapy anito-cel since 2022. This therapy was designed to provide better safety, which would be an advantage over Carvykti, the blockbuster multiple myeloma product marketed by Johnson & Johnson and Legend Biotech. The post Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma…

Read More

Relapses Don’t ‘Happen in Clinics’: Empathy Health Technologies Secures $7.6M for Sobriety App

Empathy Health’s $7.6 million round was led by HealthX Ventures and included participation from Nina Capital, Ikigai Healthcare Funds, American Heart Association Ventures, Suncoast Ventures, Cortado Ventures and Wilson Sonsini Investment Company. The post Relapses Don’t ‘Happen in Clinics’: Empathy Health Technologies Secures $7.6M for Sobriety App appeared first on MedCity News.

Read More